StocksFundsScreenerSectorsWatchlists
TXMD

TXMD - TherapeuticsMD Inc Stock Price, Fair Value and News

1.88USD-0.01 (-0.53%)Market Closed

Market Summary

TXMD
USD1.88-0.01
Market Closed
-0.53%

TXMD Stock Price

View Fullscreen

TXMD RSI Chart

TXMD Valuation

Market Cap

21.8M

Price/Earnings (Trailing)

-2.12

Price/Sales (Trailing)

16.74

EV/EBITDA

-2.56

Price/Free Cashflow

-0.94

TXMD Price/Sales (Trailing)

TXMD Profitability

EBT Margin

-11.07%

Return on Equity

-35.09%

Return on Assets

-23.73%

Free Cashflow Yield

-105.89%

TXMD Fundamentals

TXMD Revenue

Revenue (TTM)

70.0M

Rev. Growth (Yr)

27.9%

Rev. Growth (Qtr)

6.92%

TXMD Earnings

Earnings (TTM)

-10.3M

Earnings Growth (Yr)

-101.14%

Earnings Growth (Qtr)

73.86%

Breaking Down TXMD Revenue

52 Week Range

1.884.72
(Low)(High)

Last 7 days

-10.4%

Last 30 days

-17.8%

Last 90 days

-16.7%

Trailing 12 Months

-48.1%

How does TXMD drawdown profile look like?

TXMD Financial Health

Current Ratio

1.72

TXMD Investor Care

Shares Dilution (1Y)

20.78%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202352.8M35.6M18.5M1.3M
202267.8M45.1M57.5M70.0M
202172.5M84.8M90.9M87.0M
202058.0M62.6M58.2M64.9M
201916.3M18.6M38.8M49.6M
201816.6M16.1M15.1M16.1M
201718.4M18.3M17.1M16.8M
201620.6M20.2M20.5M19.4M
201516.7M17.8M18.8M20.1M
201410.3M11.7M13.6M15.0M
201305.5M7.1M8.8M
20122.3M2.6M3.1M3.8M
20111.5M1.7M1.9M2.1M
20100001.2M

Tracking the Latest Insider Buys and Sells of TherapeuticsMD Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 07, 2023
walker marlan d
sold
-10,187
2.239
-4,550
chief executive officer
Dec 06, 2023
walker marlan d
sold
-33,496
2.3101
-14,500
chief executive officer
Dec 05, 2023
walker marlan d
acquired
-
-
70,000
chief executive officer
Nov 15, 2023
rubric capital management lp
acquired
2,000,000
2.28
877,192
-
Aug 17, 2023
ziegler joseph
acquired
-
-
7,500
principal financial officer
Jun 28, 2023
rubric capital management lp
acquired
1,150,000
3.6797
312,525
-
Apr 26, 2023
walker marlan d
sold
-2,517
3.6381
-692
chief executive officer
Apr 26, 2023
walker marlan d
acquired
-
-
2,744
chief executive officer
Apr 12, 2023
walker marlan d
sold
-4,275
3.6543
-1,170
chief executive officer
Apr 12, 2023
donegan michael c
acquired
-
-
50,000
prin. fin. and acctg. officer

1–10 of 50

Which funds bought or sold TXMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Banque Cantonale Vaudoise
unchanged
-
-
2,000
-%
Mar 11, 2024
VANGUARD GROUP INC
added
0.61
-291,390
872,059
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
-6.00
18.00
-%
Feb 15, 2024
BARCLAYS PLC
new
-
-
-
-%
Feb 14, 2024
AMERIPRISE FINANCIAL INC
reduced
-0.08
-17,359
50,579
-%
Feb 14, 2024
ADAR1 Capital Management, LLC
new
-
612,360
612,360
0.22%
Feb 14, 2024
Guardian Wealth Management, Inc.
unchanged
-
-1.00
5.00
-%
Feb 14, 2024
Clearline Capital LP
added
2.38
-326,297
1,048,980
0.06%
Feb 14, 2024
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC
sold off
-100
-47,169
-
-%
Feb 14, 2024
J. Goldman & Co LP
unchanged
-
-10,442
30,515
-%

1–10 of 41

Are Funds Buying or Selling TXMD?

Are funds buying TXMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TXMD
No. of Funds

Unveiling TherapeuticsMD Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 17, 2023
rubric capital management lp
25.73%
2,946,908
SC 13D/A
Jun 30, 2023
rubric capital management lp
19.57%
2,069,716
SC 13D/A
Aug 30, 2022
rubric capital management lp
18.27%
1,721,953
SC 13D/A
Jul 08, 2022
blackrock inc.
1.4%
122,138
SC 13G/A
Jun 03, 2022
beryl capital management llc
1.5%
126,229
SC 13G
Mar 23, 2022
smith robert j
5.38%
23,103,292
SC 13D/A
Feb 14, 2022
price t rowe associates inc /md/
0.1%
649,807
SC 13G/A
Feb 01, 2022
blackrock inc.
5.9%
24,894,812
SC 13G/A
Jul 07, 2021
flynn james e
4.90%
20,662,810
SC 13G
Feb 16, 2021
price t rowe associates inc /md/
6.2%
18,869,212
SC 13G/A

Recent SEC filings of TherapeuticsMD Inc

View All Filings
Date Filed Form Type Document
Mar 29, 2024
8-K
Current Report
Mar 29, 2024
10-K
Annual Report

Peers (Alternatives to TherapeuticsMD Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
348.8B
85.2B
-7.62% -10.06%
9.92
4.1
6.46% 95.94%
317.6B
60.1B
3.25% 9.20%
870.05
5.28
1.40% -97.49%
143.5B
46.5B
-8.33% -37.34%
-103.34
3.08
42.59% -114.62%
141.5B
28.2B
-2.53% 7.29%
21.07
5.02
7.09% 2.52%
83.4B
27.1B
-8.60% -20.08%
14.73
3.08
-0.60% 23.36%
14.8B
15.8B
-0.90% 54.57%
-25.67
0.93
6.17% 76.47%
MID-CAP
4.1B
4.7B
0.13% -17.24%
-320.54
0.87
4.58% 90.97%
4.0B
1.7B
-12.75% -17.88%
11.28
2.41
49.61% 324.78%
3.2B
8.8B
-7.68% 16.09%
-5.35
0.36
7.79% -163.11%
1.9B
644.4M
-6.53% -6.23%
14
2.99
29.14% 50.51%
SMALL-CAP
1.3B
743.2M
-10.42% -30.36%
-3.78
1.79
24.65% 80.36%
21.8M
1.3M
-17.83% -48.08%
-2.12
16.74
-98.14% -109.18%
17.1M
-
-12.17% 23.93%
-0.93
0.22
2882.68% -138.52%
2.5M
19.6M
-33.93% -94.71%
-0.18
0.13
80.00% 43.08%
422.3K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

TherapeuticsMD Inc News

Latest updates
Defense World13 Apr 202406:19 am
Defense World07 Apr 202406:20 am

TherapeuticsMD Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue6.9%502,000469,500437,000414,750392,500370,250348,000695,00018,678,00025,406,00023,001,00019,866,00022,578,00019,342,00010,701,00012,251,00015,902,00023,719,0006,079,0003,947,0005,089,000
Gross Profit1047.2%502,000-53,000437,000416,00061,329,500--14,473,00013,941,00020,124,00018,869,00015,179,00016,997,00016,063,0006,301,0009,536,00013,023,00022,275,0004,830,0003,184,0004,139,000
Operating Expenses22.8%2,113,0001,720,0002,909,0003,083,00020,124,00014,519,00014,857,00017,875,000-77,802,00060,045,00054,048,00044,457,00051,604,00041,037,00051,339,00060,458,00057,414,53749,346,68346,466,87841,288,90242,259,406
  S&GA Expenses-7.2%1,476,0001,590,0002,781,0003,056,00010,343,00014,246,00014,575,00017,546,000-5,445,00030,005,00032,164,00024,024,00016,799,50022,373,00029,887,00057,189,000-7,147,51945,126,98641,387,45134,864,08235,410,875
  R&D Expenses------1,112,0001,580,0001,400,0001,420,0001,605,0002,011,0002,050,0002,394,0002,027,0002,742,0003,269,0004,432,0124,077,7384,964,3686,317,8826,753,190
EBITDA Margin-112.1%-0.090.770.580.410.260.11-0.40-0.55-0.62-1.47-1.41-1.80-2.34--------
Interest Expenses-675.0%-115,00020,00045,00050,00010,863,000--5,364,000-273,0007,518,0007,596,00010,227,0007,612,0007,680,0007,027,0006,262,0005,664,3685,599,0054,028,6092,090,0182,093,375
Income Taxes------295,000-260,000550,000--------------
Earnings Before Taxes-10.5%-1,584,000-1,434,000-2,414,000-2,310,00048,453,000-14,631,000-14,873,000-17,875,00050,150,000-47,420,000-42,652,000-39,383,000-42,087,000-32,612,000-51,976,000-56,849,000-49,435,515-31,966,593-55,236,517-39,506,375-39,390,981
EBT Margin-118.3%-0.110.600.420.240.020.05-0.67-0.85-0.91-1.89-1.85-2.29-2.83--------
Net Income73.9%-883,000-3,378,000-2,414,000-3,603,00077,702,000-28,965,000112,281,000-49,021,000-42,960,000-47,420,000-42,652,000-39,383,000-42,087,000-32,612,000-51,976,000-56,849,000-49,435,000-31,967,000-55,237,000-39,506,000-39,391,000
Net Income Margin-115.0%-0.150.980.612.251.60-0.15-0.60-2.69-1.98-1.89-1.85-2.29-2.83--------
Free Cashflow17.7%-4,960,000-6,028,000-3,392,000-8,701,00030,236,00017,716,000-20,700,000-17,914,00048,002,000-38,153,000-26,573,000-38,443,000-30,525,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-14.2%43.0050.0054.0060.0090.00134146133169210211239182177206269266250247182212
  Current Assets-32.4%12.0017.0020.0025.0055.0087.0099.0084.00119160160187128122149212208192216153187
    Cash Equivalents-91.2%4.0049.0049.0049.0049.0065.0065.0065.0065.0010511113880.0080.00114170161155183123162
  Inventory------7.006.009.008.007.008.007.008.0010.0010.0015.0012.0011.007.005.003.00
  Net PPE-100.0%-0.000.000.000.001.001.001.001.001.002.002.002.002.002.002.003.002.001.001.000.00
Liabilities-37.5%14.0022.0022.0028.0055.00182172274263267260249306293300314257271238121114
  Current Liabilities-52.8%7.0015.0014.0019.0047.0017416426525386.0076.0061.0059.0047.0046.0062.0053.0067.0042.0045.0041.00
  Long Term Debt----------17217517923823724424319519419474.0073.00
    LT Debt, Current------94.0091.0020318815.0010.005.00---------
    LT Debt, Non Current----------17217517923823724424319519419474.0073.00
Shareholder's Equity4.4%29.0028.0031.0032.0035.00----93.62-------9.00-8.0061.0098.00
  Retained Earnings-0.1%-949-948-945-942-939-1,017-988-1,100-1,051-1,008-960-918-878-836-804-752-695-645-614-558-519
  Additional Paid-In Capital0.2%979977977975974969962960958951912908755721710707704625622619617
Accumulated Depreciation-3.00---2.00----------------
Shares Outstanding9.0%12.0011.0011.0010.009.009.009.009.009.008.008.007.006.00--------
Float---34.00---87.00---445---308---539--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations17.7%-4,960-6,028-3,392-8,70130,23617,716-20,721-17,87248,002-38,223-26,532-38,380-30,357-34,049-55,954-39,111-50,817-26,222-50,514-38,163-28,144
  Share Based Compensation-50.4%1162344384832,9854,2922,2342,0615,3467,3122,5102,9575,245--2,3665,40356.0056.002,5874,434
Cashflow From Investing------74.007.00-76.00-212-1,514-182-89.00-438-494-262-399-443-20,713-1,302-1,210-665-671
Cashflow From Financing200300.0%2,002-1.00---111,9451,739-120,000-5,0001,35331,82242895,94931,70310694.0048,82277,0319.00111,687100430

TXMD Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue, net:  
Total revenue, net$ 1,302$ 69,963
Cost of revenue1,397
Gross profit1,30268,566
Operating expenses:  
Selling, general and administrative8,90356,710
Depreciation & amortization9221,193
Restructuring9,472
Total operating expenses9,82567,375
Income (loss) from operations(8,523)1,191
Other income (expense):  
Miscellaneous income (expense)781(117)
Total other income (loss), net781(117)
Income (loss) from continuing operations before income taxes(7,742)1,074
Benefit (provision) for income taxes43
Net income (loss) from continuing operations(7,699)1,074
Income (loss) from discontinued operations, net of income taxes(2,579)110,923
Net income (loss)$ (10,278)$ 111,997
Income (loss) per common share, basic:  
Continuing operations (in Dollars per share)$ (0.74)$ 0.12
Discontinued operations, net (in Dollars per share)(0.25)12.29
Net income (loss) per common share, basic (in Dollars per share)(0.98)12.41
Income (loss) per common share, diluted:  
Continuing operations (in Dollars per share)(0.74)0.11
Discontinued operations, net (in Dollars per share)(0.25)11.84
Net income (loss) per common share, diluted (in Dollars per share)$ (0.98)$ 11.96
Weighted average common shares, basic (in Shares)10,4419,028
Weighted average common shares, diluted (in Shares)10,4419,366
Net income (loss)$ (10,278)$ 111,997
Other comprehensive income
Comprehensive income (loss):(10,278)111,997
License and service revenue  
Revenue, net:  
Total revenue, net$ 1,302$ 69,963

TXMD Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]  
Cash and cash equivalents$ 4,327$ 38,067
Restricted cash11,250
Royalty receivable, current portion3,090
Prepaid and other current assets4,0356,034
Current assets of discontinued operations344
Total current assets11,79655,351
Fixed assets, net78
License rights and other intangible assets, net6,0986,943
Royalty receivable, long term18,48420,253
Other non-current assets58253
Right of use assets6,8737,580
Total assets43,30990,458
Accounts payable272,162
Accrued expenses and other current liabilities3,13318,846
Current liabilities of discontinued operations3,69425,831
Total current liabilities6,85446,839
Operating lease liabilities, non-current6,5327,369
Other non-current liabilities6361,107
Total liabilities14,02255,315
Commitments and contingencies (Note 8)
Common stock, par value $0.001; 32,000 and 12,000 shares authorized, 11,532 and 9,498 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively119
Additional paid-in capital978,917974,497
Accumulated deficit(949,641)(939,363)
Total stockholders’ equity29,28735,143
Total liabilities and stockholders’ equity$ 43,309$ 90,458
TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
 WEBSITEtherapeuticsmd.com
 INDUSTRYPharmaceuticals
 EMPLOYEES1

TherapeuticsMD Inc Frequently Asked Questions


What is the ticker symbol for TherapeuticsMD Inc? What does TXMD stand for in stocks?

TXMD is the stock ticker symbol of TherapeuticsMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TherapeuticsMD Inc (TXMD)?

As of Wed Apr 17 2024, market cap of TherapeuticsMD Inc is 21.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TXMD stock?

You can check TXMD's fair value in chart for subscribers.

What is the fair value of TXMD stock?

You can check TXMD's fair value in chart for subscribers. The fair value of TherapeuticsMD Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TherapeuticsMD Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TXMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TherapeuticsMD Inc a good stock to buy?

The fair value guage provides a quick view whether TXMD is over valued or under valued. Whether TherapeuticsMD Inc is cheap or expensive depends on the assumptions which impact TherapeuticsMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TXMD.

What is TherapeuticsMD Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, TXMD's PE ratio (Price to Earnings) is -2.12 and Price to Sales (PS) ratio is 16.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TXMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on TherapeuticsMD Inc's stock?

In the past 10 years, TherapeuticsMD Inc has provided -0.385 (multiply by 100 for percentage) rate of return.